Profectus BioSciences, Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality caused by viral diseases, today announced that it has completed an additional $3 million private equity placement with the sale of securities to private investors led by Cross Atlantic Capital Partners.
Business Wire
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Zimmer Biomet’s 3D Printed Titanium Spinal Implant Receives 510(k) Clearance
The system includes surgical tools to insert, move and remove the implants.
Senate Subcommittee Advances $5.4 Billion FDA Spending Bill
The full Senate appropriations committee will consider the bill on Thursday.
FDAnews Drug Daily Bulletin
PROFECTUS BIOSCIENCES, INC. ANNOUNCES ADDITIONAL $3 MILLION PRIVATE PLACEMENT OF EQUITY SECURITIES
May 31, 2006